2020-04-04 12:31:591970-01-01 00:00:00

Industry News

& Articles

Clinuvel Pharmaceuticals Accelerates Offshore Expansion


Global biopharmaceutical company, Clinuvel Pharmaceuticals, has announced that it will be expanding its facilities in Singapore to be equipped with state-of-the-art laboratories due to open on 01 July 2020. The Singapore Economic Development Board (EDB) has awarded research & development grant to the firm’s wholly-owned subsidiary Vallaurix Pte Limited, which will be expanded through both an analytical and biological laboratory. Additionally, both labs will work operate under Good Laboratory Practice (GLP) and ISO 17025 specifications.

Headquartered in Melbourne, Clinuvel is satisfied with the support it has received regarding its expansion plans. The plans are also in line with the government's plans in assisting corporations to develop research capacity, further advancing high valued technologies. The award is up to $547,000 over three years.

The firm has also witnessed a surge in company value to that of $2.2 billion after massive buying triggered by US Food & Drug Administration’s (FDA) decision. The federal agency has given the green light for the company’s drug, Scenesse to be used on patients in the vast US market. Scenesse is a slow-release implant approximately the size of a grain of rice that initiates the production of melanin – human’s natural shield against ultra-violet light.

Specifically, the primary purpose of the drug seeks to treat adult patients who have been diagnosed with the rare metabolic disorder known as Erythropoietic Protoporphyria (EPP). More importantly, Scenesse will also aim to increase pain-free light exposure in adult EPP patients who have a track record of phototoxicity.

In light of the outbreak of the deadly coronavirus, Clinuvel has reached out to assure customers that the supply of its Scenesse remains unaffected. More notably, the synthetic peptide, which is the key active ingredient in the drug, continues to be manufactured under good manufacturing practice (GMP) conditions within the European Union. Measures surrounding quality control of the drug have also been put in place where further laboratory tests are conducted before it is released and distributed to patients and hospitals.

The FDA has also confirmed on 03rd March 2020 that it has confirmed the date where discussions surrounding the North American development program for Scenesse for the pigment loss disorder vitiligo would occur. Presently, the meeting is due to take place on 29 April 2020 and expects to witness the attendance of global vitiligo professionals.

2019 was a significant milestone for Clinuvel as it was the year where the firm made it to the ASX 200. The firm now has a similar value to telecommunication Vocus Communications and property group, Charter Hall. More broadly speaking, the FDA’s approval is deemed momentous given that the regulatory path to approval spanned across a decade, starting with Europe back in 2006. Likewise, the firm’s achievements were reflected in its results for the half-year ended 31 December 2019 where net profits came in at $1.059 million – Clinuvel’s eighth consecutive half-year profit.

By Caroline Wong 

Click here for a 7 days access to our Lotus Blue Portal.

Comment on this company

Latest Stories

Coronavirus Boosts Sales For Fisher & Paykel’s Respiratory Products

As the global coronavirus cases surpassed the 1 million mark, merely 20 per cent among all victims.. …

Kogan.com Benefits As Consumers Resort To Online Shopping

Back in Mid-February, shares in Kogan have slumped after CEO Ruslan Kogan indicated that his.. …

Woolworths Extends Helping Hand To Those In Need

Amid the current pandemic, supermarket giant, Woolworths Limited (WOW) is widely regarded…..

More for you

Austal Limited Plays Critical Role in US National Defence

Australia’s shipbuilder and contractor for some of the most advanced defence vessels has been.. …

Smartgroup Outperforms Despite Industry Headwinds

Salary packaging and administration services company, Smartgroup has been faced…..

Energy and Industrial Services Push Seven Group Higher

In its first-half report, the industrial services and energy sectors outperformed other aspects…..

Link Administration Suspends Earnings Guidance

Link Administration Holdings Limited (Link Group) has finalised its agreement to acquire Pepper…..

Altium Limited On Track To Achieve Goals

Altium Limited, one of ASX ‘WAAAX’ tech stocks along with WiseTech, Afterpay, Appen.. …

Reliance Worldwide Downgrades Earnings Guidance

Back in 2019 when President Donald Trump announced plans to increase tariffs in the…..

KOSEC Terms & Conditions

Kodari Securities Pty Ltd (CAR 399556) trading as KOSEC is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC is a financial services company and any information provided by its platforms, portals, reports and documents is protected by copyright. Any unauthorised production of this information is prohibited.
KOSEC reserves the right to change or remove any information provided on our website, reports or any documents including these terms and conditions at any time without notice. The change or modification to the terms and conditions will be effective immediately upon posting an updated version on our website, necessary platforms and documents. It is recommended that you review the information provided on our website, including these terms and conditions frequently for any changes.

KOSEC provides general advice only. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. KOSEC recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Please make sure you read our Financial Services Guide (FSG).

KOSEC does not guarantee any returns. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance). Investing in the stock market can incur huge losses. Please also be aware that fees will incur on every transaction regardless of the performance of your investments or returns generated. Employees and or associates of KOSEC may hold one or more of the stocks, securities or investments reviewed by the company.

Your use of information from our website, reports, documents and from talking to our representatives/associates is at your risk. Under no circumstance should the investment be based solely on KOSEC information and general advice. You should seek professional financial planning advice.
KOSEC aims to maintain the accuracy of the data and information provided on this website, by using information prepared from a wide variety of sources, which KOSEC to the best of its knowledge and belief, considers accurate and does not make any representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.

We may at times refer to third parties, which the details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market. KOSEC has no control over the information third parties have, or the products or services offered, and therefore make no representations regarding the accuracy or suitability of such information, products or services. You are advised to make your own enquiries in relation to third parties. Our inclusion of any third party content is not an endorsement of that content or the third party.

As a client you will be charged a yearly service fee and a set brokerage fee per transaction. Your service fee will automatically renew at the end of your agreed 12 month period at the same rate advertised at the time. Your credit card or bank account will be charged for a further year following which will again auto renew until you cancel your yearly service fee. You can cancel the auto renewal at any time in advance of the renewal date by contacting us. KOSEC is aware of the need to ensure the security of your credit card details and our payment systems are compliant with the Payment Card Industry (PCI) Data Security Standard.

You consent to receiving email correspondence from KOSEC, as well as companies KOSEC has an association with. These emails will be sent by KOSEC and third party companies. You can opt out of receiving any category of emails at any time by contacting us. We may from time to time inform you of special offers, or even ask your opinion of the services we provide, but your involvement is optional. Should you request us to do so, we will archive your details.

Indemnity and Liability
You indemnify KOSEC from all claims or threatened claims, suits, demands, damages, costs as well as including legal costs incurred in dealing with any threatened claim, expenses made by any person or corporation against KOSEC and any other amounts which is caused by KOSEC providing information, execution and General Advice.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from a decision made by you on the basis of information obtained through the use of our portal, reports, documents or any General Advice given and any transaction taken place.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from delays in executing orders for the client and acknowledges KOSEC makes no guarantees about the time taken to execute an order on behalf of the client. You acknowledge that KOSEC relies on third parties in providing technology and release KOSEC from any harm, loss or damage you may suffer as a result of the failure of such information technology.

Cookies and Links
KOSEC website, and its portal uses cookies, which lets us identify your browser while you are using the site or our portal. Cookies do not identify you personally. They simply allow us to track your usage patterns. If you prefer not to receive cookies, you can configure your browser to reject them or to notify you when they are being used. The functionality of the KOSEC website may be impacted if you restrict the use of cookies.

Fill up the form below and we will get back to you as soon as possible.



KOSEC’s CEO, Michael Kodari’s new book, “Stock Market Success” valued at $39.95, available at Dymocks book stores with all the proceeds going to Dymocks Children’s Charities.


Latest TV Commercial